(Oslo, 24th of March 2020) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the REQUEST study has now been published in the Journal of Thoracic and Cardiovascular Surgery (JTCVS).
The REQUEST study is a multicentre, prospective study among 7 international centers performing coronary artery bypass grafting procedures. The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the rate and reason for surgical changes related to the aorta, in situ conduits, coronary targets, and completed grafts, and the rate of in-hospital mortality and major morbidity.
1016 patients were included in the final analyses. Surgical changes related to the aorta, conduits, coronary targets, and anastomosis were made in 25% of patients. This was associated with low operative mortality and low major morbidity. The authors concluded that “transit-time flow measurement (TTFM) and high-frequency ultrasound (HFUS) may improve the quality, safety, and efficacy of coronary artery bypass grafting procedures and should be considered as a routine procedural aspect.”
“Although the results from the REQUEST study have been available on-line and presented at several key conferences around the world during 2019, we are delighted to see the study finally printed in JTCVS, a journal highly recognized by cardiac surgeons,” says Medistim President and CEO, Kari E. Krogstad. “This marks the finish line for a large clinical study performed by highly regarded and experienced coronary surgeons in this field, and their support for routine use of TTFM and HFUS will be of great value to the further endorsement and technology adoption across the globe.”
View the REQUEST study here: https://www.jtcvs.org/article/S0022-5223(19)31581-8/abstract
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com